Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparing the Effects of Anakinra and Tocilizumab on Outcomes in Patients With New-Onset Refractory Status Epilepticus

NCT07281027 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT07281027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07281027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparing the Effects of Anakinra and Tocilizumab on Outcomes in Patients With New-Onset Refractory Status Epilepticus
Lead sponsor
Yale University
Phase
Phase 3
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
September 30, 2030
Enrollment
438 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

febrile infection-related epilepsy syndrome (fires), new onset refractory status epilepticus, new-onset refractory status epilepticus